Abstract |
A phase I, single-center, open-label, dose-escalation study (University of Alabama [UAB] 9614) has been undertaken to evaluate the feasibility and safety of uracil and tegafur (in a molar ratio of 4: 1 [UFT]) plus oral calcium folinate (Orzel) plus radiotherapy in patients with pancreatic cancer. A total of 11 patients with a median age of 59 years have been treated for 35 days with 150 mg/m2/day of UFT and 90 mg/day of oral calcium folinate, divided into three daily doses. Radiotherapy began on day 1, to a total dose of 45 Gy at 1.8 Gy per day (for approximately 5 weeks). Dose escalation of UFT will be performed until the maximum tolerated dose is defined. Overall, therapy has been well tolerated and the maximum tolerated dose has not yet been reached.
|
Authors | F Robert, D Raben, S Spencer |
Journal | Oncology (Williston Park, N.Y.)
(Oncology (Williston Park))
Vol. 13
Issue 7 Suppl 3
Pg. 127-8
(Jul 1999)
ISSN: 0890-9091 [Print] United States |
PMID | 10442381
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Tegafur
- Uracil
- Leucovorin
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Follow-Up Studies
- Humans
- Leucovorin
(therapeutic use)
- Middle Aged
- Pancreatic Neoplasms
(drug therapy, mortality, radiotherapy)
- Radiotherapy, Adjuvant
- Safety
- Survival Rate
- Tegafur
(therapeutic use)
- Treatment Outcome
- Uracil
(therapeutic use)
|